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Although efforts to identify novel therapies for the treatment of tuberculosis have led
to the identification of several promising drug candidates, the identification of high-
quality hits from conventional whole-cell screens remains disappointingly low. The
elucidation of the genome sequence of Mycobacterium tuberculosis (Mtb) facilitated
a shift to target-based approaches to drug design but these efforts have proven largely
unsuccessful. More recently, regulated gene expression systems that enable dose-
dependent modulation of gene expression have been applied in target validation to
evaluate the requirement of individual genes for the growth of Mtb both in vitro and in
vivo. Notably, these systems can also provide a measure of the extent to which putative
targets must be depleted in order to manifest a growth inhibitory phenotype. Additionally,
the successful implementation of Mtb strains engineered to under-express specific
molecular targets in whole-cell screens has enabled the simultaneous identification
of cell-permeant inhibitors with defined mechanisms of action. Here, we review the
application of tetracycline-regulated gene expression systems in the validation of novel
drug targets in Mtb, highlighting both the strengths and limitations associated with this
approach to target validation.
Keywords: Mycobacterium tuberculosis, drug discovery, regulated gene expression, hypomorphs, target
validation, target-based whole cell screening
Tuberculosis (TB) remains a major global health crisis, with 9 million new cases and 1.5 million
deaths attributable to this disease in 2013 (WHO, 2014). The treatment of TB is challenging,
requiring combination therapy with rifampicin, isoniazid, pyrazinamide, and ethambutol for
2 months, followed by an additional 4 months of treatment with rifampicin and isoniazid.
Despite this extended period of treatment, however, strains of Mycobacterium tuberculosis (Mtb)
resistant to rifampicin and isoniazid, deﬁned as multidrug-resistant (MDR), continue to emerge,
with an estimated 480,000 cases of MDR-TB identiﬁed in 2013 (WHO, 2014). The more recent
emergence of MDR strains with additional resistance to ﬂuoroquinolones and at least one of the
injectable aminoglycosides (amikacin, kanamycin, or capreomycin) – termed extensively drug-
resistant (XDR) – has resulted in the need to implement therapies that must be continued for
up to 24 months, and involve the use of more costly, less eﬀective, and more toxic second-line
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drugs. Thus, the emergence and spread of drug-resistant strains
of Mtb has complicated the already daunting challenge of global
TB control, and has underscored the urgent need to identify
new anti-tubercular agents with novel mechanisms of action
(Zumla et al., 2013). This need has driven the establishment
of a TB drug pipeline, which is populated with a number of
promising candidates and novel drug combinations at various
stages of clinical development. However, the typically high
attrition rate for drugs in clinical development, coupled with
speciﬁc weaknesses in the TB drug pipeline – in particular, the
paucity of candidates in the early stages of clinical validation –
makes the development of new drug regimens for the treatment
of drug-resistant as well as drug-susceptible TB critically reliant
upon replenishment of the pipeline through the identiﬁcation of
high-quality “hit” compounds and novel targets by innovative TB
drug discovery programs.
In the target-based approach to TB drug discovery,
compounds that inhibit the biochemical function of the
target of interest are identiﬁed by high-throughput screening
(HTS) of compound libraries or by structure-guided drug
design (Hung et al., 2009; Willand et al., 2009; Krieger et al.,
2012). While this approach has yielded compounds with potent
inhibitory activity against validated targets, the compounds
frequently fail to display whole-cell activity against live bacilli
(Payne et al., 2007; Cole and Riccardi, 2011; Xu et al., 2014).
This problem is commonly attributed to issues of permeation,
metabolism, and eﬄux, all of which are likely exacerbated by
the comparatively complex intracellular environment in which
the drug-target interaction must occur in a cell-based assay.
In the alternative, phenotypic approach, cell-based HTS of
compound libraries has been used to identify inhibitors with
whole-cell activity against Mtb in vitro. This approach has been
considerably more successful (Stover et al., 2000; Matsumoto
et al., 2006; Makarov et al., 2009; Pethe et al., 2013; Manjunatha
et al., 2015), and led to the recent development of bedaquiline
(Sirturo; Andries et al., 2005), the ﬁrst FDA-approved drug for
the treatment of TB in over 40 years (Cohen, 2013); delamanid
(Deltyba), which received conditional approval by the European
Medicines Agency in 2013 and is being evaluated in a phase 3
trial for the treatment of MDR-TB (Gler et al., 2012); and PA-824
(pretomanid), which has shown promise as part of a new three-
drug regimen (Dawson et al., 2015). Importantly, hit compounds
discovered through phenotypic screens have been used to
identify novel targets in previously unexploited pathways,
such as AtpE (target of bedaquiline) and QcrB (targeted by
imidazopyridines other chemotypes) in energy metabolism, and
DprE1 (benzothiazinones and other chemotypes) in arabinan
biosynthesis (Andries et al., 2005; Petrella et al., 2006; Makarov
et al., 2009; Magnet et al., 2010; Abrahams et al., 2012b; Stanley
et al., 2012; Pethe et al., 2013; Preiss et al., 2015). However,
deducing mechanisms of action of inhibitors with whole-cell
activity can often be challenging, particularly if the inhibitory
eﬀects are pleiotropic (Kohanski et al., 2008) or if the target is
not a protein (Ling et al., 2015).
A fundamental requirement of a desirable antimicrobial drug
target is that it should have an essential, and preferably non-
redundant, function in growth and pathogenesis of the organism.
The study of (conditionally) essential gene function in bacteria
has been revolutionized by the development of regulated gene
expression systems, which enable the expression of a target
gene to be controlled in a manner that depends upon the
level of an inducer. A number of such systems have been
developed for use in mycobacteria, and have been employed
to investigate the roles of a wide variety of genes essential
and conditionally essential for bacillary growth, physiology, and
metabolism (Gomez and Bishai, 2000; Greendyke et al., 2002;
Dziadek, 2003; Trauner et al., 2012; Ventura et al., 2013; Chuang
et al., 2015). In this review, we focus on the use of tetracycline
(Tet)-regulated gene expression systems in Mtb, speciﬁcally in
the context of target validation. We highlight the technical
advancements that have been made, and describe the application
of conditional mutants of Mtb in the validation of novel drug
targets, and in target-based whole-cell screening (TB-WCS), in
which phenotypic and target-based approaches are combined to
identify target- and pathway-selective compounds with whole-
cell activity.
Tet-Regulated Genetic Switches for
Controlling Gene Expression in Mtb
Regulated gene expression systems have been extensively
characterized and utilized in both Gram-positive and Gram-
negative bacteria (Bertram and Hillen, 2008), yet limited
knowledge of the transcriptional regulatory mechanisms and
machinery complicated the development of such systems
for use in mycobacteria until relatively recently. The ﬁrst
successful demonstration of dose-responsive gene expression
in mycobacteria was achieved by expressing the 35 kDa
antigen of M. leprae from the acetamide-inducible promoter
of Mycobacterium smegmatis (Msm; Parish et al., 1997; Triccas
et al., 1998). This system has since been used successfully to
express several mycobacterial proteins in Msm (Gomez and
Bishai, 2000; Ojha et al., 2000; Parish et al., 2001; Daugelat
et al., 2003; Dziadek, 2003; Ahidjo et al., 2011; Lee et al.,
2014); however, instability in Mtb has limited its utility in this
species (Brown and Parish, 2006). Several other regulated gene
expression systems, including those mediated by Tet, nitrile,
and pristinamycin, have subsequently been developed for use in
mycobacteria (Table 1A); these have been reviewed elsewhere
(Schnappinger and Ehrt, 2014) so will not be described here.
In this review, we focus speciﬁcally on the Tet-regulated gene
expression systems (Table 1B; Blokpoel et al., 2005; Carroll et al.,
2005; Ehrt et al., 2005), which have been widely applied, and
whose utility in TB drug discovery is enhanced by the fact that
they can be used to regulate gene expression in animal models of
infection.
The mechanism of transcriptional regulation using Tet-
controlled genetic switches is based on that of a family of
Tet-exporting proteins that mediate resistance to Tet in Gram-
negative organisms (Berens and Hillen, 2003). In the absence
of Tet, Tet repressor (TetR) proteins bind tightly to the Tet
operators (tetO) located within the promoter of tetA, encoding
the Tet-exporting protein, thereby suppressing tetA expression
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TABLE 1 | Regulated gene expression systems developed for use in Mycobacterium tuberculosis (Mtb).
Expression system Regulatory components Reference
Promoter Regulator
(A) Gene regulation systems utilized in mycobacteria
Tet-ON Tet-inducible promoter of tetA from
Corynebacterium glutamicum
TetR repressor from C. glutamicum Blokpoel et al. (2005)
Tet-ON Tet-inducible promoter Pxyl from
Bacillus subtilis
Tn10-derived TetR repressor from
Escherichia coli
Carroll et al. (2005)
NitR Nitrile-inducible promoter of nitA from
Rhodococcus rhodochrous
NitR regulator, both from
R. rhodochrous
Pandey et al. (2009)
Pip-ON Pristinamycin-inducible promoter, Pptr,
from Streptomyces pristinaespiralis
Pristinamycin-responsive repressor,
Pip, from S. coelicolor
Forti et al. (2009)
Tet/Pip-OFF Pristinamycin-inducible promoter, Pptr,
from S. pristinaespiralis
Pristinamycin-responsive repressor,
Pip, from S. coelicolor under control of
Tet-inducible promoter, PfurA102tetO
Boldrin et al. (2010)
(B) Tetracycline (Tet)-regulated gene expression systems optimized for use in mycobacterial gene regulation
Tet-ON Tet-inducible mycobacterial promoter,
Pmyc1tetO
Tn10-derived TetR repressor from
E. coli
Ehrt et al. (2005)
Tet-OFF Tet-inducible mycobacterial promoter,
Pmyc1tetO
Tn10-derived reverse TetR inducer from
E. coli
Guo et al. (2007)
FIGURE 1 | Schematic representation of tetracycline (Tet) export in
Gram-negative bacteria. In the absence of Tet, Tet repressor (TetR) dimers
bind to Tet operators (tetO) located upstream of tetA, encoding the
Tet-exporting protein, repressing its transcription. Upon introduction of
anhydrotetracycline (ATc) and its subsequent binding to TetR, a
conformational change occurs that results in dissociation of TetR from tetO,
enabling Tet-mediated transcription of tetA to occur. Tet is then transported
across the cytoplasmic membrane by TetA.
(Figure 1; Berens and Hillen, 2003). Owing to the substantially
higher aﬃnity of TetR for Tet than for the ribosome (Lederer
et al., 1996), the introduction of Tet causes a conformational
change that results in dissociation of TetR from tetO, leading
to de-repression of tetA and ultimately to the eﬄux of Tet
(Berens and Hillen, 2003). By replacement of the native Mtb
promoter of a gene of interest with a Tet-regulatable promoter,
and introduction of TetR on a replicating or integrative plasmid,
dose-dependent induction of gene expression can be mediated
through the addition of varying concentrations of the less
toxic derivative, anhydrotetracycline (ATc; Blokpoel et al., 2005;
Carroll et al., 2005; Ehrt et al., 2005). Since it is important
that introduction of the inducer has a minimal eﬀect on the
expression of other genes, an additional advantage of the Tet-
regulated system is that gene expression can be induced with ATc
concentrations at least 10-fold below the concentration required
to inhibit the growth of Msm or Mtb (Ehrt and Schnappinger,
2006).
Conditional knockdown mutants – or “hypomorphs” – in
which expression of the target gene is switched on upon addition
of ATc are commonly referred to as “Tet-ON” mutants; in this
conﬁguration, removal of the inducer is required in order to
silence target gene expression (Figure 2A). The dynamic range
of the Tet-ON system can be expanded further by expression
of TetR from either a strong promoter or an intermediate-
strength promoter to generate hypomorphs in the Tet-ONS
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FIGURE 2 | Tetracycline-mediated gene regulation in Mycobacterium
tuberculosis (Mtb). (A) In the Tet-ON configuration, TetR dimers bind to Tet
operators (tetO) in the absence of ATc, repressing transcription. Upon
introduction of ATc and its subsequent binding to TetR, a conformational change
occurs that results in dissociation of TetR from tetO, enabling Tet-mediated
transcription from Pmyc1tetO to occur. (B) In the Tet-OFF configuration,
introduction of ATc results in binding of revTetR to Pmyc1tetO, causing repression
of transcription. TetR, Tet repressor; ATc, anhydrotetracycline; tetO, Tet
operator; Pmyc1tetO, mycobacterial promoter with tetOs inserted; revTetR,
reverse Tet repressor (Adapted from Guo et al., 2007).
and Tet-ONM conﬁgurations, respectively. This increases the
ﬂexibility of the system, enabling dose-dependent regulation
of genes with widely diﬀering levels of expression. Since the
removal of ATc can be diﬃcult to achieve in some experimental
settings, the manipulation of Tet-dependent hypomorphs was
greatly simpliﬁed by the development of a modiﬁed “Tet-OFF”
system, which utilizes a mutated, “reverse” TetR (revTetR) that
binds to tetO only in the presence of ATc (Guo et al., 2007).
This system enables the generation of mutants in which target
gene expression is repressed upon addition of the ATc inducer
(Figure 2B). The regulatory capacity of both Tet-ON and Tet-
OFF systems in mycobacteria has been enhanced by codon
optimization of the genes encoding TetR and revTetR to allow
increased expression in Mtb (Klotzsche et al., 2009). Together,
these modiﬁcations have provided a means of evaluating the
eﬀects of transcriptional silencing of target genes on growth and
viability of the organism.
Application of Tet-Regulated Systems in
Target Validation
The utility of genetic switches for regulating gene expression in
Mtb was ﬁrst demonstrated by the generation of a tryptophan
auxotroph following Tet-mediated transcriptional silencing of
trpD (Carroll et al., 2005). Transcriptional silencing has
subsequently been used to conﬁrm the in vitro essentiality of
a variety of genes in Mtb, thus providing preliminary genetic
validation of the encoded proteins as potential drug targets.
These include, among others, fatty-acid-coenzyme A (CoA) ligase
(fadD32; Carroll et al., 2011), diaminopimelate decarboxylase
(lysA; Abrahams et al., 2012a), Clp protease (clpP1; Ollinger et al.,
2012b), pantothenate synthetase (panC; Abrahams et al., 2012a),
thymidylate synthase (thyX; Singh et al., 2015), ribonucleotide
reductase (nrdF2; Singh et al., 2015), topoisomerase I (Rv3646c;
Ahmed et al., 2014) and seven genes (dprE1, dprE2, ubiA,
prsA, Rv2361c, tkt, and rpiB) involved in decaprenyl-phospho-
D-arabinofuranose (DPA) biosynthesis in Mtb (Kolly et al.,
2014a).
A major advantage of Tet-regulated systems is that the
ability of ATc to diﬀuse across biological membranes also allows
these systems to be used to regulate expression of Mtb genes
in infected macrophages (Blokpoel et al., 2005; Ehrt et al.,
2005). Furthermore, the pharmacokinetic properties of ATc and
its analog, doxycycline (doxy), permit administration of this
inducer to animals at doses required to successfully regulate
gene expression in vivo (Ehrt and Schnappinger, 2006) without
compromising the growth of wildtype bacilli (Gandotra et al.,
2007; Blumenthal et al., 2010). Since the conditions under which
Mtb can be cultured in vitro are unlikely to fully recapitulate the
environment encountered in the host during infection, this can
have signiﬁcant eﬀects on the physiology, metabolism and global
transcriptional response of the bacilli and, hence, on the relevance
of the conclusions drawn from such analyses (Bloch and Segal,
1956; Schnappinger et al., 2003; Pethe et al., 2010; Griﬃn et al.,
2012). The development of the Tet-system therefore represented
a major breakthrough in mycobacterial genetics by providing
a means to identify genes that are (conditionally) essential for
growth ofMtb in vivo (Gandotra et al., 2007). Silencing of prcBA,
encoding the α and β subunits of the Mtb 20S proteasome,
either immediately post-infection, or during the chronic stage of
infection (i.e., following onset of the acquired immune response),
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resulted in a decline in bacillary load in the lungs and spleens of
mice, indicating a role for the proteasome in both growth and
persistence ofMtb in vivo (Gandotra et al., 2007). The successful
demonstration of the utility of this approach paved the way for a
slew of subsequent studies aimed at investigating the requirement
of several Mtb genes for growth during diﬀerent phases of
infection (Table 2), simultaneously providing genetic validation
of many of these as potential drug targets. Although perhaps not
of direct relevance to the physiology of Mtb itself, it is worth
noting that the selective inhibition of mitochondrial protein
translation by Tets can lead to altered transcriptional proﬁles
in eukaryotic cell lines and has minor eﬀects on physiological
ﬁtness in mice (Moullan et al., 2015). This may, in turn, aﬀect the
contribution of the murine immune response toMtb clearance.
An important caveat to the use of hypomorphs for conﬁrming
target essentiality both in vitro and in vivo is the potential
for suppressors to emerge that are no longer responsive to the
inducer (Stallings et al., 2009; Boldrin et al., 2010; Kolly et al.,
2014a). The loss of inducer dependence of gene expression can
arise through the acquisition of mutations in the regulatory
network and/or loss of the transcriptional repressor as a
consequence of the strong selective pressure conferred onMtb by
depletion of an essential cellular function. Since the emergence
of suppressor mutants masks the eﬀects of inducer-dependent
transcriptional silencing, it is essential to include appropriate
controls for detection of populations of bacilli that are no
longer inducer-responsive when phenotypically characterizing
hypomorphs produced using these systems.
Assessing Target Vulnerability by
Tet-Mediated Transcriptional Silencing
Genome-wide transposon mutagenesis has played a critical role
in deﬁning the genetic requirements for growth and viability
of Mtb under various conditions (Sassetti and Rubin, 2003;
Sassetti et al., 2003; Rengarajan et al., 2005; Beste et al., 2009;
Griﬃn et al., 2011). However, the complete elimination of
biochemical function resulting from insertional inactivation of
a gene encoding an essential cellular function is unlikely to be
achieved by chemical inhibition of that function, particularly
in the validation phase of drug discovery when inhibitory
activity has not yet been optimized (Barry et al., 2009). Recent
target validation eﬀorts have thus focused on determining target
“vulnerability,” which can be operationally deﬁned as the extent to
which the activity/function of a target must be reduced in order
to manifest in a growth phenotype (Figure 3A). Given increasing
evidence suggesting that targets requiring incomplete inhibition
in order to confer a lethal phenotype may bemore valuable (Barry
et al., 2009; Kim et al., 2011; Wei et al., 2011), the ability to
silence gene expression in a dose-dependent manner provides a
potentially powerful means to infer the vulnerability of a given
target.
The construction of hypomorphs by transcriptional silencing
has allowed target vulnerability to be analyzed by quantifying
the relative level of transcript depletion associated with bacterial
growth inhibition and/or loss of viability (Gandotra et al., 2007;
Forti et al., 2009; Boldrin et al., 2010; Carroll et al., 2011;
Kolly et al., 2014a). However, the kinetics of depletion of a
protein by transcriptional silencing depend upon the speciﬁc
protein half-life. Therefore, it is important to monitor the extent
of protein depletion and its association with bacterial growth
and/or viability during the course of a silencing experiment as
silencing of genes encoding long-lived proteins may result in
an underestimation of the vulnerability of those targets. It is
also important to consider the relative strengths of the inducible
promoter vs. the native promoter of the gene of interest when
constructing hypomorphs. In cases where the target protein is
in low abundance in wildtype bacilli, promoter replacement
may result in the target being expressed at a higher level from
the regulated promoter than from its native promoter under
conditions of maximal de-repression. In such cases, eﬃcient
TABLE 2 | Targets validated by Tet-mediated control ofMtb gene expression in vivo.
Gene Protein Function Phase of infection Reference
prcBA Proteasome α and β
subunits
ATP-dependent degradation of damaged proteins Chronic Gandotra et al. (2007),
Blumenthal et al. (2010)
pckA Phosphoenolpyruvate
carboxykinase
Catalyzes the first committed step in gluconeogenesis Acute and chronic Marrero et al. (2010)
icl1 Isocitrate lyase Catalyzes the conversion of isocitrate to glyoxylate and
succinate in the first step of the glyoxylate shunt
Acute and chronic Blumenthal et al. (2010)
Rv3671c Serine protease Role in protection from oxidative stress and acidification Chronic Blumenthal et al. (2010)
pptT 4′-phosphopantetheinyl
transferase
Transfer of 4′-phosphopantetheine group from Coenzyme A
(CoA) to acyl carrier proteins
Acute and chronic Leblanc et al. (2012)
fba Fructose-1,6-bisphosphate
aldolase (FBA)
Reversible cleavage of fructose-1,6-bisphosphate to yield
dihydroxyacetone phosphate and glyceraldehyde 3-phosphate
in glycolysis and gluconeogenesis
Acute and chronic Puckett et al. (2014)
pimA Phosphatidyl-myo-inositol
mannosyltransferase
Transfer of mannosyl residue from GDP-Man to
phosphatidyl-myo-innositol
Acute and chronic Boldrin et al. (2014)
relA GTP-pyrophosphokinase Synthesis of (p)ppGpp Acute and chronic Weiss and Stallings (2013)
carD Transcriptional regulator Regulates transcription initiation Srivastava et al. (2013) Acute and chronic Stallings et al. (2009)
bioA 7,8-diaminopelargonic acid
synthase
Catalyzes the antepenultimate step in biotin biosynthesis Acute and chronic Woong Park et al. (2011)
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FIGURE 3 | The application of hypomorphs in (A) assessing target
vulnerability and (B) expanding antitubercular chemical space.
(A) Dose-dependent silencing of a target gene enables determination of the
extent to which that target must be depleted in order to result in growth
inhibition. A target that requires only 50% depletion in order to reduce 50% of
bacterial growth (black line) is considered more vulnerable that one that
requires 75% depletion to achieve the same effect (gray line). (B) Reduction of
the absolute concentration of a target by conditional knockdown (gray line)
relative to wildtype levels (black line) facilitates the identification of on-target
inhibitors by lowering the minimum inhibitory concentration (MIC).
silencing is unlikely to be achieved (Ehrt and Schnappinger, 2006;
Carroll et al., 2011). The converse may also occur, as observed
in the case of icl1, which encodes isocitrate lyase, a key enzyme
in the glyoxylate shunt. Icl1 is conditionally essential for growth
of Mtb on fatty acids and is transcriptionally upregulated when
the organism is cultured on acetate (Munoz-Elias andMcKinney,
2005; Blumenthal et al., 2010). Replacement of the native icl1
promoter with the Tet-regulated promoter, Pmyc1tetO, resulted
in a 16-fold increase in sensitivity of Mtb to the Icl inhibitor,
3-nitropropionate (3-NP), when grown on acetate, most likely
reﬂecting a signiﬁcantly lower level of icl1 expression by the
Tet-regulated promoter than the native (fatty-acid-inducible)
promoter (Abrahams et al., 2012a).
Transcriptional silencing has been used to infer relative
invulnerability for a number of potential drug targets for which
small molecule inhibitors have been developed. For example,
pantothenate kinase (PanK), the enzyme that catalyzes the ﬁrst,
and rate-limiting, step in the conversion of pantothenate (vitamin
B5) into CoA (Das et al., 2006), has attracted considerable
attention as a TB drug target (Begley et al., 2001; Spry et al.,
2008; Moolman et al., 2014). Although essential for growth of
Mtb in vitro (Sassetti et al., 2003; Griﬃn et al., 2011; Reddy
et al., 2014), and despite the fact that transcriptional silencing
of panK (coaA) resulted in depletion of PanK protein to below
the limit of detection, growth of Mtb in liquid culture and in
vivo was not impeded (Reddy et al., 2014). A similar approach
was used to show that >95% depletion of another enzyme in
the CoA biosynthesis pathway, pantothenate synthetase (PanC),
is required to eﬀect complete growth inhibition of Mtb in vitro
(Abrahams et al., 2012a). Likewise, in the case of the biotin
biosynthesis enzyme, BioA, which is essential for growth in
vitro and persistence of Mtb in mice (Sassetti et al., 2003;
Woong Park et al., 2011), >95% depletion of the protein was
required in order to completely inhibit Mtb growth (Woong
Park et al., 2011). These results suggest that PanK, PanC, and
BioA represent relatively invulnerable targets in Mtb and, since
complete inactivation of a target’s function by a small molecule
inhibitor is not readily achievable, this may account, at least in
part, for the lack of whole-cell activity of known inhibitors of
these enzymes against wildtypeMtb (Ciulli et al., 2008; Abrahams
et al., 2012a; Bjorkelid et al., 2013; Reddy et al., 2014; Park
et al., 2015). However, it is important to recognize that while
knowledge of the relative vulnerabilities of potential targets –
as inferred from target depletion studies – can be useful in
terms of guiding target-based approaches to drug design, this
notion is of less relevance in the case of an inhibitor that
binds irreversibly to, or induces a conformational change in,
its target. This point is illustrated in the case of BioA and the
antibiotic, amiclenomycin: despite the relative invulnerability
of BioA suggested by transcriptional silencing, amiclenomycin
is able to bind covalently to this protein, thereby rendering it
irreversibly inactive, which results in growth inhibition of Mtb
(Sandmark et al., 2002; Woong Park et al., 2011).
A Pathway Approach to Prioritizing
Novel Drug Targets
There is renewed interest in targeting core metabolic pathways in
Mtb for drug discovery (Murima et al., 2014; Puckett et al., 2014;
Trujillo et al., 2014). In this context, the ability to rank enzymes
in a prioritized metabolic or biosynthetic pathway on the basis
of relative vulnerability can be particularly useful for focusing
eﬀorts. An excellent example of the value of this approach comes
from a study on the biosynthesis of DPA, a precursor of the
arabinogalactan component the mycobacterial cell wall (Kolly
et al., 2014a). DPA biosynthesis in Mtb takes place in ﬁve steps
involving eight genes (Wolucka, 2008; Kolly et al., 2014a), all but
one of which are predicted to be required for bacillary growth
(Sassetti et al., 2003; Griﬃn et al., 2011). The epimerase DprE1,
which catalyzes the ﬁfth and ﬁnal step in the DPA biosynthesis
pathway in conjunction with DprE2 (Wolucka, 2008; Kolly et al.,
2014a), has been identiﬁed as the target of several new classes
of inhibitors that display potent anti-tubercular activity, and has
been rigorously validated as a novel TB drug target (Christophe
et al., 2009; Makarov et al., 2009; Magnet et al., 2010; Stanley
et al., 2012; Wang et al., 2013). To identify the steps in the DPA
pathway that are most vulnerable to target depletion, Kolly et al.
(2014a) generated conditional knockdown mutants in every gene
and compared the eﬀects of transcriptional silencing of each on
the growth and viability ofMtb in vitro and in macrophages.
This study revealed that, in addition to dprE1, transcriptional
silencing of ubiA, encoding the decaprenyl-phosphate
phosphoribosyltransferase UbiA, and prsA, encoding the
phosphoribosyl pyrophosphate (PRPP) synthetase PrsA,
exhibited the most profound growth inhibitory eﬀects, with
Frontiers in Microbiology | www.frontiersin.org 6 August 2015 | Volume 6 | Article 812
Evans and Mizrahi Mtb hypomorphs in target validation
depletion of each resulting in a loss of Mtb viability in vitro
and in macrophages. While the cidality associated with
transcriptional silencing of drpE1 and ubiA in vitro was shown
to occur as a result of induction of cell lysis, silencing of prsA
resulted in reduced viability through cell implosion, without
lysis occurring. Interestingly, although cell death occurred more
slowly upon depletion of UbiA or PrsA than DprE1, the decrease
in nucleic acid and protein synthesis observed as a consequence
of PrsA depletion suggested that the bactericidal eﬀects of PrsA
inhibition are likely to be pleiotropic, thus identifying this
enzyme as another promising a target in the DPA pathway.
However, in an exciting new development, DprE1 was shown
to occupy an extracytoplasmic location in Mtb, suggesting
that cellular localization may be a major determinant of the
vulnerability of DprE1 to chemical inhibition, accounting for the
potency of the many inhibitors that act on this target (Brecik
et al., 2015).
Target Depletion by Tet-Mediated
Regulated Protein Degradation
To overcome the limitations associated with using promoter
replacement mutants for target depletion by transcriptional
silencing, powerful new methods have been devised to enable
regulated protein degradation in mycobacteria as an alternative
approach (Kim et al., 2011; Wei et al., 2011). Although only
reported thus far in Msm, this method nonetheless warrants
discussion here owing to its obvious applicability in the validation
of novel targets in Mtb. Proteolytic degradation complexes play
an important role in protein quality control in bacteria by
recognizing and degrading misfolded proteins. InMtb, the ATP-
dependent intracellular ClpXP proteolytic complex, which is
essential for growth in vitro (Sassetti et al., 2003; Raju et al., 2012)
and during infection (Raju et al., 2012), mediates degradation
of SsrA-tagged proteins (Figure 4A; Raju et al., 2012). The
recognition of aberrant proteins by ClpXP is further enhanced
by binding of an adapter protein, SspB, to SsrA-tagged proteins
(Levchenko et al., 2000). Mutation of the ClpX-binding region
of the SsrA tag to generate a modiﬁed tag, DAS+4, which
carries a terminal DAS sequence in place of the LAA sequence
in wildtype SsrA, weakens the interaction between ClpX and
the targeted protein, resulting in SspB-dependent proteolysis
of the tagged protein (Figure 4B; Griﬃth and Grossman,
2008). Through elegant manipulation of the mycobacterial
Clp protease system, Kim et al. (2011) demonstrated that
degradation of DAS+4-tagged proteins could be induced by
TetR-mediated induction of SspB in Msm (Figure 4C). Using
this system, dose-dependent Tet-regulated depletion of RpoB
was achieved by insertion of a DAS+4 tag at the 3′ end of
the rpoB gene, which encodes the target of the ﬁrst-line anti-
TB drug, rifampicin. Importantly, targeted degradation of RpoB
had the same bactericidal eﬀect on Msm as treatment with
rifampicin.
A variation of this approach was subsequently employed
to compare the eﬀects of regulated degradation of RpoB
and ﬁve other well-validated antimycobacterial drug targets –
GyrA, the target of the ﬂuoroquinolones; Alr, a target of
D-cycloserine; dihydrofolate reductase (DHFR), the target of
trimethoprim; InhA, the target of isoniazid; and KasA, the target
of thiolactomycin – on the growth and viability of Msm (Wei
et al., 2011). This study revealed that the rates of depletion of
the six targets varied considerably (Wei et al., 2011): while InhA,
Alr, and DHFR were undetectable following 3 h of incubation
in the presence of the inducer, little eﬀect was seen on levels
of RpoB, GyrA, and KasA up to 6 h post-treatment. Moreover,
the degree of protein depletion observed did not correlate with
bacterial survival: whereas 80% reduction of RpoB was suﬃcient
to arrest the growth of Msm, >97% depletion of DHFR and
Alr – as measured by immunoblotting and conﬁrmed by enzyme
activity analysis – had only modest eﬀects on growth (Wei et al.,
2011). Subsequent to this landmark study, regulated protein
degradation has been use to validate a number of other drug
targets inMsm, including those involved in nicotinamide adenine
dinucleotide (NAD) biosynthesis (Rodionova et al., 2014),
peptidoglycan biosynthesis (Gee et al., 2012) and intracellular
protein degradation (Raju et al., 2012). Importantly, however, the
varying eﬀects of depleting pharmacologically validated targets of
known TB drugs onMtb viability calls for caution when using the
outcome of regulated protein degradation studies as a primary or
sole criterion for ranking, prioritizing or discarding novel drug
targets.
Tightened Regulation using a
Tet-Mediated Dual Control System and
its Application in the Validation of
Persistence Targets
Most eﬀorts in TB drug discovery remain centered on identifying
inhibitors of cellular processes required for bacillary growth
under various conditions (Makarov et al., 2009; Hartkoorn
et al., 2012; Blanco et al., 2015; Manjunatha et al., 2015).
However, the critical role that populations of bacilli that are
non-replicating or slowly replicating are thought to play in
TB disease (Barry et al., 2009; Rittershaus et al., 2013) has
underscored the need to identify those cellular functions that
are critical for maintaining these “persister” populations as
well as inhibitors that act on them. Hypomorphs have a
particularly important role to play in assessing the contribution
of speciﬁc targets during diﬀerent stages of disease progression,
including the chronic stage, in which the rate of bacillary
replication is markedly reduced (Gill et al., 2009). However,
the relatively frequent generation of hypomorphs of Mtb in
which growth is able to proceed unimpeded, even under
conditions of maximal transcriptional silencing (Carroll et al.,
2005, 2011; Woong Park et al., 2011; Kumar et al., 2012),
can complicate the genetic validation of putative persistence
targets in vivo. This problem is illustrated in the case a
bioA hypomorph, which, despite the requirement of BioA for
growth of Mtb in vitro (Sassetti et al., 2003; Woong Park
et al., 2011) and in mouse spleen (Sassetti and Rubin, 2003),
showed no growth phenotype when transcriptionally silenced
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FIGURE 4 | Tetracycline-mediated regulated protein degradation in
Msm. (A) Degradation of SsrA-tagged proteins by ClpXP is enhanced by the
adapter protein, SspB. (B) Mutation of the wildtype LAA ClpX recognition site of
SsrA to generate a modified DAS tag weakens the interaction of ClpXP with the
aberrant protein, resulting in SspB-dependent proteolysis of the tagged protein.
(C) By replacement of the native sspB promoter with a Tet-inducible promoter,
SspB-mediated degradation of proteins that have been engineered to carry a
modified DAS tag can be achieved upon induction with ATc.
in vivo owing to residual bioA expression at a level suﬃcient
to sustain bacillary growth. In this example, mutation of the
ribosome binding site upstream of bioA to create a weaker
translation initiation signal resulted in dose-dependent growth
of the bioA hypomorph in vitro and attenuation of growth in
mouse lung (Woong Park et al., 2011), thus providing a strategy
for overcoming the challenges associated with transcriptional
leakiness.
An alternative strategy for addressing transcriptional leakiness
is to use a modiﬁed version of the Tet-regulated system that
allows simultaneous transcriptional repression of a target gene
and degradation of the encoded protein, resulting in a more
tightly regulated system (Kim et al., 2013; Kolly et al., 2014b). In
the dual-control (DUC) system, expression of sspB is regulated
by TetR, and is thus repressed in the absence of ATc, while
expression of the target gene is regulated by revTetR, allowing it
to be expressed in the absence of ATc (Figure 5A). Upon addition
of the ATc inducer, transcription of sspB proceeds, leading to Clp-
mediated proteolysis of the DAS+4-tagged target protein and
simultaneous transcriptional silencing of the target gene through
binding of revTetR to the Tet-regulated promoter (Figure 5B).
The biological utility of the DUC system was conﬁrmed by
generating a BioA-DUC mutant, which showed faster kinetics of
killing than achievable by transcriptional silencing or targeted
proteolysis alone and also resulted in the reduced emergence
of suppressors that were no longer inducer-responsive (Kim
et al., 2013). A similar approach, using a modiﬁed version of
the Pip/Tet-OFF regulated gene expression system (Table 1) in
combination with SspB-mediated Clp proteolysis, was used to
conﬁrm the essentiality of the transketolase, Tkt, for growth of
Mtb both in vitro and in macrophages (Kolly et al., 2014b). This
system also demonstrated more rapid killing than transcriptional
silencing alone (Kolly et al., 2014b), conﬁrming the need to
consider protein half-life when utilizing transcriptional silencing
as a measure of target vulnerability.
Importantly, as control of the DUC system is Tet-mediated,
it can also be applied in vivo to provide a powerful means
of evaluating the requirement of a protein for persistence of
Mtb during chronic infection, with reduced risk of suppressors
masking the phenotype. Kim et al. (2013) used this approach
to demonstrate the absolute requirement of NAD synthetase
(NadE) for non-replicating persistence of Mtb in vitro, and to
conﬁrm that its inactivation is bactericidal. Furthermore, the
rapid decline in bacillary load in the lungs and spleens of both
acute and chronically infected mice upon inactivation of NadE
indicated that inhibition of NadE could kill Mtb in several, if
not all, of the metabolic states adopted during murine infection
(Kim et al., 2013), further validating this enzyme as a drug target
(Boshoﬀ et al., 2008). The DUC genetic switch has also been used
to validate fructose-1,6-bisphosphate aldolase (FBA), a central
enzyme in glycolysis and gluconeogenesis inMtb, as a persistence
target (Puckett et al., 2014).
Target-Based Whole-Cell Screening
An important application of hypomorphs is in target-based
whole-cell screening (TB-WCS). The rationale underlying this
approach is that a reduction in the concentration of a target may
render the cell hypersensitive to inhibitors that act on that target.
Firstly, hypomorphs can be applied in drug susceptibility testing
of individual compounds to provide biological conﬁrmation of
target speciﬁcity. The utility of TB-WCS for conﬁrming target
speciﬁcity in Mtb was ﬁrst demonstrated by the observation that
dose-dependent silencing of dprE1 resulted in hypersensitivity
to benzothiazinones (Carroll et al., 2011), which are known
inhibitors of DprE1 (Makarov et al., 2009). Subsequently,
transcriptional silencing in Mtb has been used to conﬁrm the
target-speciﬁcity of PanC inhibitors designed through fragment-
based approaches (Hung et al., 2009; Abrahams et al., 2012a);
PanC (Kumar et al., 2013) and DHFR (Kumar et al., 2012)
inhibitors identiﬁed from high-throughput biochemical screens;
a LepB inhibitor previously shown to have increased eﬃcacy
against an Escherichia coli lepB knockdown (Barbosa et al.,
2002; Ollinger et al., 2012a); and hydroxyurea, as an inhibitor
of the class Ib ribonucleotide reductase (Singh et al., 2015).
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FIGURE 5 | Dual-control (DUC) genetic switch for simultaneous
transcriptional silencing and degradation of the encoded protein in Mtb.
(A) In the absence of ATc sspB expression is repressed by TetR, while
expression of the target gene under control of revTetR proceeds. (B) Upon
introduction of ATc, sspB transcription proceeds, enabling ClpXP-mediated
proteolysis of the target protein and simultaneous transcriptional repression of
the target gene due to binding of revTet to the Tet-regulated promoter. tetR, Tet
repressor; GOI, gene of interest; rev tetR, reverse Tet repressor; ATc,
anhydrotetracycline; ClpXP, protease complex mediating controlled proteolysis
of the target protein (Adapted from Kim et al., 2013).
As outlined above, the discovery that the natural product,
amiclenomycin, inhibits Mtb through covalent inactivation
of BioA (Sandmark et al., 2002) has heightened interest in
this particular target. However, amiclenomycin has signiﬁcant
liabilities, being chemically unstable, highly polar (Shi et al.,
2011), and inactive againstMtb in in a mouse model of infection
(Kitahara et al., 1975). To identify other scaﬀolds targeting BioA
whose potency could potentially be enhanced by structure-based
drug design to generate analogs with in vivo eﬃcacy, Aldrich
and colleagues (Park et al., 2015) used a BioA hypomorph
to analyze the 255 hits identiﬁed by screening a 350,000-
compound library for inhibitors of this enzyme. Their results
were encouraging: while the majority of hits identiﬁed from the
biochemical screen showed no whole-cell activity against Mtb,
several showed enhanced activity against the BioA hypomorph,
conﬁrming that these compounds were on-target in Mtb (Park
et al., 2015).
Target-based whole-cell screening has also found application
in enabling the direct identiﬁcation of novel, cell-permeable
inhibitory scaﬀolds with whole-cell activity against deﬁned
targets or pathways through screening of large compound
libraries. The hits may include inhibitors of non-catalytic sites
in an enzyme target. They may also include chemotypes that
would escape detection in screens against wildtype cells by virtue
of their weak inhibitory activity, thus increasing the availability
of chemical matter for lead identiﬁcation (Figure 3B). The
feasibility of TB-WCS as a tool for identifying novel antibacterial
agents was ﬁrst demonstrated by the discovery of the type
II fatty acid synthesis (FASII) inhibitor, platensimycin, which
showed enhanced activity against Staphylococcus aureus isolates
in which fabF transcript was conditionally depleted by antisense-
mediated interference (Wang et al., 2006; Young et al., 2006).
Although TB-WCS has been used with some success in other
bacteria (DeVito et al., 2002; Wang et al., 2006; Young et al.,
2006; Phillips et al., 2011), it has only recently been applied in
Mtb (Abrahams et al., 2012a). In the only example published
to date, a panC hypomorph was screened against a ∼14,000-
compound library which led to the identiﬁcation of a series of
ﬂavones that displayed increased potency against PanC-depleted
cells relative to wildtype Mtb. It was subsequently shown that
these compounds do not directly inhibit PanC, despite the
fact that pantothenate – the product of the PanC enzyme –
rescuedMtb from the toxic eﬀects of the compounds (Abrahams
et al., 2012a). This result conﬁrmed that the eﬀect of target
depletion can extend beyond hypersensitization of the target
itself, and may, for example, hypersensitize downstream enzymes
in the same metabolic pathway to chemical inhibition through
substrate depletion or diversion of metabolic ﬂux (Palmer and
Kishony, 2014). In the case of PanC, the potential for oﬀ-target
hypersensitization owing tometabolic remodeling is even greater,
as depletion of this target leads to CoA depletion, which may,
in turn, result in hypersensitization of any number of CoA-
dependent enzymes. Target de-convolution in cases such as this
may be challenging.
In addition to this potential complication, there are a
number of other issues that should be taken into account when
considering the use of TB-WCS for hit identiﬁcation in TB drug
discovery. Firstly, it is critical to monitor and conﬁrm stability
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of the hypomorph during the course of the phenotypic screen
as the emergence of suppressors that are no longer inducer-
dependent will compromise the screen. Secondly, as highlighted
recently (Palmer and Kishony, 2014), an alteration in the level
of expression of a target does not always manifest in a predictably
altered susceptibility to a drug that acts on that target, particularly
for cases in which the mechanism of action is complex. The
ﬂuoroquinolones provide an interesting case in point: these drugs
act by trapping gyrase-DNA complexes, resulting in inhibition
of DNA synthesis and growth arrest, followed by cell death
upon release of double-stranded DNA breaks from trapped
gyrase complexes (Drlica and Zhao, 1997). As such, conditional
depletion of GyrA is not expected to confer ﬂuoroquinolone
hypersensitivity on mycobacteria (Wei et al., 2011). Finally, as
for any phenotypic screen, the diﬀerential requirement of genes
for growth under speciﬁc conditions (Pethe et al., 2010; Mak
et al., 2012; Beste et al., 2013) must also be taken into account
for TB-WCS. As an example, transcriptional silencing of icl1
resulted in Tet-dependent growth impairment of Mtb on acetate
as the sole carbon source and hypersensitivity to 3-NP, but had
no eﬀect on growth of 3-NP susceptibility when cultured on
glucose.
Limitations in using Hypomorphs to
Simulate Chemical Inhibition
While the utility of hypomorphs in TB drug discovery has been
convincingly demonstrated, variability between individual targets
can sometimes make data interpretation diﬃcult. Furthermore,
the concept of genetic validation is predicated on the assumption
that a perturbation in the cellular concentration of a target
by transcriptional silencing or proteolytic degradation is a
reasonable surrogate for the inhibitory eﬀect of a chemical
inhibitor of the target’s function. In reality, the genetic vs.
chemical vulnerability of a target may diﬀer considerably as a
result of a variety of factors (Wei et al., 2011). These include the
local concentration of drug required for eﬀective inhibition of
the target and the time needed for the successful perturbation
of the target (Lu and Tonge, 2010), both of which are likely to
relate to the abundance of the target. The former is of particular
signiﬁcance in the case of Mtb, whose sequestration in remote
lesion compartments in the human host likely accounts for the
lack of correlation observed between plasma pharmacokinetics
and drug eﬃcacy (Kjellsson et al., 2012; Lakshminarayana et al.,
2015). The latter is important with regard to using genetic
approaches to simulate chemical inhibition since the kinetics of
chemical inhibition are signiﬁcantly faster than those of gene
silencing. While targeted protein degradation (Kim et al., 2011,
2013; Wei et al., 2011; Kolly et al., 2014b) has the potential to
more accurately estimate target vulnerability by better simulating
the kinetics of chemical inhibition (Kim et al., 2011, 2013;
Kolly et al., 2014b), this approach has its own limitations: in
particular, it involves modiﬁcation of the C-terminus of the target
protein, which could aﬀect the structure, function and abundance
of the target. The recent development of a clustered regularly
interspaced short palindromic repeat interference (CRISPRi)
approach to regulating gene expression in Mtb has the potential
to overcome these limitations in that the transcriptional level of
the target is maintained no modiﬁcation of the expressed protein
is required (Choudhary et al., 2015).
The potential disconnect between depletion of a target by
genetic means and its pharmacologic inhibition is perhaps
best illustrated in the case of DHFR, the target of the folate
biosynthesis inhibitor, trimethoprim. Although overexpression
of DHFR in both E. coli (Palmer and Kishony, 2014) and
Msm (Bhat et al., 2013) was shown to result in decreased
susceptibility to trimethoprim, targeted depletion of DHFR by
proteolytic degradation in Msm did not phenocopy treatment
with trimethoprim (Wei et al., 2011). One possible explanation
is that chemical inhibition of DHFR by trimethoprim is more
eﬃcient than targeted proteolysis. Alternatively, trimethoprim
could have multiple targets, requiring simultaneous inhibition
of all in order to mediate growth inhibition. To distinguish
these possibilities, the metabolomic consequences of DHFR
depletion and treatment with sub-inhibitory concentrations of
trimethoprim were compared. The production of the same
metabolite proﬁles in both cases conﬁrmed that DHFR is in fact
the primary target of trimethoprim (Wei et al., 2011) suggesting
that, in this case, even regulated degradation of the DHFR is not
able to accurately recapitulate the phenotypic consequences of
chemical inhibition of the enzyme.
Concluding Remarks
Given that less than a decade ago there were no robust
genetic switches available for regulation of gene expression
in Mtb, remarkable progress has been made in this area.
Hypomorphs provide an eﬀective means of genetically validating
novel drug targets, of comparing selected mutants in terms of
vulnerability and of evaluating the downstream consequences of
loss of target function. However, other factors such as cellular
localization and druggability, which are critically important in
determining target access by small molecule inhibitors, must also
be taken into account when ranking and prioritizing novel drug
targets, particularly in a pathway context. The implementation
of regulated protein degradation systems and DUC genetic
switches provide enhanced stringency while simultaneously
enabling more rapid kinetics of inactivation, thus providing a
powerful means of validating new drug targets. The increasing
accessibility of ‘omics approaches oﬀer exciting prospects for
combining metabolomic and proteomic analyses with genetic
approaches for target validation, which, when coupled with
live-cell imaging of bacilli undergoing target depletion or drug
treatment, have the potential to provide key insights into the
global eﬀects that disruption of an essential cellular function can
have upon bacterial metabolism and physiology. Whether the
systems reviewed here have a role in validating targets in animal
models other than mice, which more accurately recapitulate the
pathology of human disease, remains to be seen. Nonetheless,
the encouraging results obtained to date, suggest that conditional
mutants are set to play an increasingly important role in early
stage TB drug discovery.
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